News Conference News ACC 2023 MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis Michael O'Riordan March 10, 2023
News Conference News ACC 2023 No Downside to Immediate Complete Revascularization in ACS: BIOVASC Michael O'Riordan March 06, 2023
Presentation ACC 2023 Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III) Presenter: Annapoorna S. Kini March 06, 2023
Presentation ACC 2023 Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease Presenter: Roberto Diletti March 05, 2023
News Conference News ACC 2023 Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III Shelley Wood March 04, 2023
News Conference News ACC 2023 STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy L.A. McKeown March 04, 2023
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2022 FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses Michael O'Riordan April 06, 2022
News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News ACC 2020 PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years Michael O'Riordan March 30, 2020
News Conference News ACC 2020 More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA Michael O'Riordan March 28, 2020
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI Michael O'Riordan March 21, 2017